Insight Molecular Diagnostics | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 260 K

Revenue: As of FY2025 Q3, the actual value is USD 260 K, missing the estimate of USD 285 K.

EPS: As of FY2025 Q3, the actual value is USD -0.34, missing the estimate of USD -0.21.

EBIT: As of FY2025 Q3, the actual value is USD -11.05 M.

Segment Revenue

Insight Molecular Diagnostics Inc. reported revenues of $260,000 in Q3 2025, derived from laboratory services performed at their clinical laboratory in Nashville.

Operational Metrics

• Gross profit for Q3 2025 was $139,000, representing a 53.5% gross margin.
• Operating expenses for Q3 2025 totaled $11.2 million, including $3.4 million in non-cash changes in the fair value of contingent consideration, $521,000 in non-cash stock-based compensation expenses, and $563,000 in non-cash depreciation and amortization expenses.
• Research and development expenses increased 18% sequentially to $3.9 million in Q3 2025.
• Sales and marketing expenses declined 5% sequentially to $1.4 million in Q3 2025.
• General and administrative expenses declined 4% sequentially to $2.5 million in Q3 2025.
• Net loss for Q3 2025 was $10.9 million, or - $0.34 per share.

Cash Flow

• Cash, cash equivalents, and restricted cash balance at the end of Q3 2025 was $20.2 million.
• Net cash used in operating activities for Q3 2025 was - $4.6 million.
• Capital expenditures for Q3 2025 were - $1.1 million.

Unique Metrics

• The company did not realize any kitted product revenue in Q3 2025 and does not expect material revenue from kitted product sales until regulatory clearance is achieved.

Outlook / Guidance

Insight Molecular Diagnostics Inc. is on track to submit GraftAssureDx™ for FDA review by year-end and aims to have 20 transplant centers globally engaged with GraftAssure technology by the end of 2025. The company anticipates rapid expansion beyond kidney into heart transplant testing and expects to surpass near-term financial objectives, generating sustained free cash flow and heading towards $100 million in annual high-margin revenue growing at a double-digit pace. There could be delays to the timeline due to the federal government shutdown, but the company is still preparing for a mid-2026 product launch.